welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Lee Sweeney, PhD
University of Florida
1200 Newell Drive
Gainesville, Florida, United States
Dr. Lee Sweeney is presently the Director of Myology Institute, University of Florida. His research interests are focused on molecular motors of the myosin superfamily. Most notable among his accomplishments on molecular motors are the first visualization of structural rearrangement of the myosin lever arm, a detailed analysis of how processive myosins are engineered, a demonstration of the structural changes induced by actin-binding and nucleotide release, and the discovery and molecular dissection of the only known reverse-direction myosin.
Dr. Sweeney is actively developing therapeutics for rare diseases that include both small molecule and gene therapy approaches. He serves as a consultant to a number of industry therapeutic development efforts for Duchenne muscular dystrophy and spinal muscular atrophy. In 2007, he and his collaborators at PTC Therapeutics (a small NJ biotech company) published the development of a compound (PTC 124 or ataluren) that allows read-through of nonsense mutations (premature stop codons) in a variety of genetic disease models. The drug is in clinical trials for Duchenne muscular dystrophy and Cystic Fibrosis. On May 23, 2014, ataluren was granted conditional European approval for the treatment of Duchenne muscular dystrophy (DMD), making it the first approved drug for this disease.
Dr. Sweeney is well-known in the popular press for his gene-therapy approaches to permanently block the loss of age-related muscle size and strength in mice. The technique suggests that therapies for humans could reverse the feebleness associated with old age or slow the muscle-wasting effects of muscular dystrophies.
PTC Therapeutics, Inc. – LinkedInPTC is biopharmaceutical company focused...
Helen P. Roper, MBChB, MDDr. Helen Roper is a paediatrician speci...
Sarepta Therapeutics Announces Second Year of Route 79, The Duchenne Scholarship ProgramSarepta Therapeutics, Inc., the leader i...
Sarepta shoots higher as sales of $300,000-a-year drug exceed expectationsSarepta announced second-quarter revenue...
Sarepta Therapeutics and Genethon announce a gene therapy research collaboration for the treatment of Duchenne muscu...Sarepta Therapeutics, Inc. (NASDAQ:SRPT)...
Solid Biosciences – LinkedinSolid Biosciences (Solid) is a Cambridge...
BioMarin snags cash as Sarepta skips Duchenne patent battleSarepta Therapeutics Inc. agreed to pay...